PMID- 27022276
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160329
LR  - 20200930
IS  - 1178-6930 (Print)
IS  - 1178-6930 (Electronic)
IS  - 1178-6930 (Linking)
VI  - 9
DP  - 2016
TI  - Efficacy and safety of vascular endothelial growth factor receptor tyrosine 
      kinase inhibitors in the treatment of advanced thyroid cancer: a meta-analysis of 
      randomized controlled trials.
PG  - 1167-73
LID - 10.2147/OTT.S102265 [doi]
AB  - BACKGROUND: We performed a systematic review and meta-analysis to determine the 
      efficacy and safety of the US Food and Drug Administration approved vascular 
      endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) in the 
      treatment of advanced thyroid cancer. PATIENTS AND METHODS: We included 
      prospective randomized controlled trials that compared VEGFR-TKIs with placebo 
      for advanced thyroid cancer. The endpoints included safety (fatal adverse events 
      [FAEs], treatment discontinuation, and any severe [grade 3 or 4] adverse events 
      [AEs]) and efficacy (objective response rate, progression-free survival, and 
      overall survival). The pooled relative risk (RR) or hazard ratio (HR) was 
      calculated by using either random-effects or fixed-effects models according to 
      the heterogeneity of included studies. RESULTS: A total of 1,614 advanced thyroid 
      cancer patients from five randomized controlled trials were identified for 
      analysis. Compared with placebo alone, VEGFR-TKIs significantly increased the 
      risk of treatment discontinuation (RR: 3.80, 95% confidence interval [CI]: 
      2.56-5.65, P<0.001) and any severe AEs (RR: 2.63, 95% CI: 1.72-4.03, P<0.001), 
      but not of FAEs (RR: 1.24, 95% CI: 0.65-2.39, P=0.52). The use of VEGFR-TKIs in 
      advanced thyroid cancer was associated with a significant improvement in 
      objective response rate (RR: 8.73, 95% CI: 1.72-44.4, P=0.009) and 
      progression-free survival (HR: 0.41, 95% CI: 0.27-0.61, P<0.001), with a tendency 
      to improve overall survival (HR: 0.83, 95% CI: 0.68-1.01, P=0.06). CONCLUSION: 
      The use of small-molecule VEGFR-TKIs in advanced thyroid cancer did significantly 
      increase the risk of treatment discontinuation and any severe AEs, but not of 
      FAEs, compared with placebo alone. It is important for physicians to weigh the 
      risk of toxicities as well as the potential survival benefits associated with 
      VEGFR-TKI treatment in advanced thyroid cancer patients.
FAU - Yimaer, Wufuer
AU  - Yimaer W
AD  - Department of Vascular Thyroid Surgery, Gastrointestinal Vascular Center, The 
      First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 
      Province, People's Republic of China.
FAU - Abudouyimu, Aizizi
AU  - Abudouyimu A
AD  - Department of Vascular Thyroid Surgery, Gastrointestinal Vascular Center, The 
      First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 
      Province, People's Republic of China.
FAU - Tian, Ye
AU  - Tian Y
AD  - Department of Vascular Thyroid Surgery, Gastrointestinal Vascular Center, The 
      First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 
      Province, People's Republic of China.
FAU - Magaoweiya, Sailike
AU  - Magaoweiya S
AD  - Department of Vascular Thyroid Surgery, Gastrointestinal Vascular Center, The 
      First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 
      Province, People's Republic of China.
FAU - Bagedati, Duman
AU  - Bagedati D
AD  - Department of Vascular Thyroid Surgery, Gastrointestinal Vascular Center, The 
      First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 
      Province, People's Republic of China.
FAU - Wen, Hao
AU  - Wen H
AD  - Department of Vascular Thyroid Surgery, Gastrointestinal Vascular Center, The 
      First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 
      Province, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20160307
PL  - New Zealand
TA  - Onco Targets Ther
JT  - OncoTargets and therapy
JID - 101514322
PMC - PMC4789842
OTO - NOTNLM
OT  - angiogenesis inhibitors
OT  - clinical trials
OT  - meta-analysis
OT  - thyroid cancer
OT  - toxicity
EDAT- 2016/03/30 06:00
MHDA- 2016/03/30 06:01
PMCR- 2016/03/07
CRDT- 2016/03/30 06:00
PHST- 2016/03/30 06:00 [entrez]
PHST- 2016/03/30 06:00 [pubmed]
PHST- 2016/03/30 06:01 [medline]
PHST- 2016/03/07 00:00 [pmc-release]
AID - ott-9-1167 [pii]
AID - 10.2147/OTT.S102265 [doi]
PST - epublish
SO  - Onco Targets Ther. 2016 Mar 7;9:1167-73. doi: 10.2147/OTT.S102265. eCollection 
      2016.